ArticleEBioMedicine2018
Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study.
Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development and Validation of a Radiomics Signature for Clinically Significant Portal Hypertension in Cirrhosis (CHESS1701): a Prospective Multicenter Study
Detachable String Magnetically Controlled Capsule Endoscopy for Detecting High-risk Varices in Compensated Advanced Chronic Liver Disease (CHESS1801): A Prospective Multicenter Study
MR-based Models for Noninvasive Detection of Clinically Significant Portal Hypertension in Cirrhosis (CHESS1802)
Transient Elastography (FibroTouch) for Assessing Risk of Gastroesophageal Varices Bleeding in Patients With Compensated Cirrhosis (Pan-CHESS1801): An International Multicenter Study
Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901): A Prospective Multicenter Study
A Novel Imaging Based Quantitative Model-aided Detection of Portal Hypertension in Patients With Cirrhosis (CHESS2104): A Prospective, Multicenter Study
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Role of radiomics in staging liver fibrosis: a meta-analysis.BMC medical imaging · 2024Pooled it
- Network Meta-Analysis: Noninvasive Imaging Modalities for Identifying Clinically Significant Portal Hypertension.Digestive diseases and sciences · 2022Pooled it
- Clinically Significant Portal Hypertension in Hepatocellular Carcinoma: Non-Invasive Assessment Across the Continuum.Current oncology reports · 2026Review
- Radiomics-Based Assessment of Portal Hypertension Severity and Risk Stratification of Cirrhotic Patients Using Routine CT Scans.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- [Novel advances following the integration of Baveno VII consensus definitions for the non-invasive testing of portal hypertension].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Deep-learning-based prediction of significant portal hypertension with single cross-sectional non-enhanced CT.European radiology · 2026Article
- A Noninvasive Predictive Model of Portal Hypertension in Patients with HCC Based on Clinical Features and Intra- and Peritumoral Pre-Fusion Radiomic Features.Journal of hepatocellular carcinoma · 2026Article
- A new direction in personalized medicine: multimodal joint prediction of hepatic encephalopathy risk post-TIPS.Frontiers in medicine · 2026Article
- Hepatocellular Carcinoma Risk Stratification for Cirrhosis Patients: Integrating Radiomics and Deep Learning Computed Tomography Signatures of the Liver and Spleen into a Clinical Model.Journal of clinical and translational hepatology · 2025Article
- Application of artificial intelligence in portal hypertension and esophagogastric varices.World journal of gastroenterology · 2025Review
- Role of Radiomics to Predict Malignant Transformation of Sinonasal Inverted Papilloma: A Systematic Review.Cancers · 2025Review
- Article
- CT-Derived spleen volume accurately diagnoses severe portal hypertension at HVPG thresholds of 16 mmhg.Scientific reports · 2025Article
- Vasomics of the liver.Gut · 2025Review
- Use of Noninvasive Tests to Assess Clinically Significant Portal Hypertension and Response to Beta-Blockers.Gastro hep advances · 2025Review
- A combination model of CT-based radiomics and clinical biomarkers for staging liver fibrosis in the patients with chronic liver disease.Scientific reports · 2024Article
- Predicting Survival Using Whole-Liver MRI Radiomics in Patients with Hepatocellular Carcinoma After TACE Refractoriness.Cardiovascular and interventional radiology · 2024Article
- Artificial intelligence in liver imaging: methods and applications.Hepatology international · 2024Review
- Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver Disease.Gut and liver · 2024Review
- Radiomic analysis of abdominal organs during sepsis of digestive origin in a French intensive care unit.Acute and critical care · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinically significant portal hypertension (CSPH) is associated with an incremental risk of esophageal varices and overt clinical decompensations. However, hepatic venous pressure gradient (HVPG) measurement, the gold standard for defining CSPH (HVPG≥10 mm Hg) is invasive and therefore not suitable for routine clinical practice. This study aims to develop and validate a radiomics-based model as a noninvasive method for accurate detection of CSPH in cirrhosis. The prospective multicenter diagnostic trial (CHESS1701, ClinicalTrials.gov identifier: NCT03138915) involved 385 patients with cirrhosis from five liver centers in China between August 2016 and September 2017. Patients who had both HVPG measurement and contrast-enhanced CT within 14 days prior to the catheterization were collected. The noninvasive radiomics model, termed rHVPG for CSPH was developed based on CT images in a training cohort consisted of 222 consecutive patients and the diagnostic performance was prospectively assessed in 163 consecutive patients in four external validation cohorts. rHVPG showed a good performance in detection of CSPH with a C-index of 0·849 (95%CI: 0·786-0·911). Application of rHVPG in four external prospective validation cohorts still gave excellent performance with the C-index of 0·889 (95%CI: 0·752-1·000, 0·800 (95%CI: 0·614-0·986), 0·917 (95%CI: 0·772-1·000), and 0·827 (95%CI: 0·618-1·000), respectively. Intraclass correlation coefficients for inter- and intra-observer agreement were 0·92-0·99 and 0·97-0·99, respectively. A radiomics signature was developed and prospectively validated as an accurate method for noninvasive detection of CSPH in cirrhosis. The tool of rHVPG assessment can facilitate the identification of CSPH rapidly when invasive transjugular procedure is not available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.